Methods for inhibiting cutaneous inflammation and hyperpigmentation
AssigneeThe Trustees of Columbia University in the City of New York
InventorB. Longley
Life of this patent
Estimating the term…
Abstract
This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat contact dermatitis so as to thereby prevent or treat contact dermatitis in the subject. This invention also provides a method of preventing or treating in a subject hyperpigmentation, asthma, cutaneous inflammation, anaphylaxis and bronchospasm, mastocytosis, tumors which express activated kit, and conception.
Claims5
A method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat contact dermatitis so as to thereby prevent or treat contact dermatitis in the subject.
2-42. (canceled)
A method of desensitizing a subject to an agent which comprises administering to the subject during the afferent phase of an immune response an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to desensitize the subject to the agent so as to thereby desensitizing the subject to the agent.
A method of identifying a composition, a compound, or a procedure which can produce a skin response in a subject, comprising:
- a) administering said composition or compound, or applying said procedure to the transgenic mice which express endogenous epidermal stem cell factor;
- and
- b) analyzing the skin of said transgenic mice for response.
45-90. (canceled)
Dependencies are inferred from the claim text.